Worsening alopecia areata and de novo occurrence of multiple halo nevi in a patient receiving infliximab.
Fabre
C
C
Dereure
O
O
D000328:Adult; D000506:Alopecia Areata / Q000139:chemically induced* / Q000473:pathology; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D003937:Diagnosis, Differential; D005500:Follow-Up Studies; D006801:Humans; D000069285:Infliximab; D007262:Infusions, Intravenous; D008297:Male; D009508:Nevus, Pigmented / Q000139:chemically induced* / Q000473:pathology; D013167:Spondylitis, Ankylosing / Q000188:drug therapy; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab